ACS Medicinal Chemistry Letters
INSERM 892-CNRS 6299 Centre de Recherche en Cancer
ologie Nantes-Angers, 8 quai Moncousu, BP70721, F-44007
Nantes Cedex, France.
Letter
phenylalanine tetrafluorophenyl ester: preparation of a radiolabeled
phenylalanine derivative for peptide synthesis. Bioconjugate Chem.
1993, 4 (6), 574−580.
(12) Lockett, M. R.; Phillips, M. F.; Jarecki, J. L.; Peelen, D.; Smith,
L. M. A tetrafluorophenyl activated ester self-assembled monolayer for
the immobilization of amine-modified oligonucleotides. Langmuir
2008, 24 (1), 69−75.
(13) Zhang, W.; Curran, D. P. Synthetic application of fluorous solid-
phase extraction (F-SPE). Tetrahedron 2006, 62 (51), 11837−11865.
(14) Donovan, A.; Forbes, J.; Dorff, P.; Schaffer, P.; Babich, J.;
Valliant, J. F. A new strategy for preparing molecular imaging and
therapy agents using fluorine-rich (fluorous) soluble supports. J. Am.
Chem. Soc. 2006, 128 (11), 3536−3537.
(15) Jin, M. Y.; Yoshikai, N. Cobalt-Xantphos-catalyzed, LiCl-
mediated preparation of arylzinc reagents from aryl iodides, bromides,
and chlorides. J. Org. Chem. 2011, 76 (7), 1972−1978.
(16) Krasovskiy, A.; Malakhov, V.; Gavryushin, A.; Knochel, P.
Eficient synthesis of functionalized organozinc compounds by the
direct insertion of zinc into organic iodides and bromides. Angew.
Chem., Int. Ed. 2006, 45 (36), 6040−6044.
́
(17) Banister, S.; Roeda, D.; Dolle, F.; Kassiou, M. Fluorine-18
chemistry for PET: A concise introduction. Curr. Radiopharm. 2010, 3
(2), 68−80.
(18) Olberg, D. E.; Arukwe, J. M.; Grace, D.; Hjelstuen, O. K.;
Solbakken, M.; Kindberg, G. M.; Cuthbertson, A. One step
radiosynthesis of 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl
ester [18F]F-Py-TFP): a new prosthetic group for efficient labeling of
biomolecules with fluorine-18. J. Med. Chem. 2010, 53 (4), 1732−
1740.
(19) Zhang, X.; He, Y.; Liu, S.; Yu, Z.; Jiang, Z. X.; Yang, Z.; Dong,
Y.; Nabinger, S. C.; Wu, L.; Gunawan, A. M.; Wang, L.; Chan, R. J.;
Zhang, Z. Y. Salicylic acid based small molecule inhibitor for the
oncogenic Srchomology-2 domain containing protein tyrosine
phosphatase-2 (SHP2). J. Med. Chem. 2010, 53 (6), 2482−2493.
(20) Cheng, Z.; Zhang, L.; Graves, E.; Xiong, Z.; Dandekar, M.;
Chen, X.; Gambhir, S. S. Small-animal PET of melanocortin 1 receptor
expression using a 18F-labeled alpha-melanocyte-stimulating hormone
analog. J. Nucl. Med. 2007, 48 (6), 987−994.
(21) Chin, F. T.; Shen, B.; Liu, S.; Berganos, R. A.; Chang, E.; Mittra,
E.; Chen, X.; Gambhir, S. S. First experience with clinical-grade
([18F]FPP(RGD2): an automated multi-step radiosynthesis for clinical
PET studies. Mol. Imaging Biol. 2012, 14 (1), 88−95.
(22) Garg, P. K.; Alston, K. L.; Welsh, P. C.; Zalutsky, M. R.
Enhanced binding and inertness to dehalogenation of alpha-
melanotropic peptides labeled using N-succinimidyl 3-iodo benzoate.
Bioconjugate Chem. 1996, 7 (2), 233−239.
(23) Chen, J.; Giblin, M. F.; Wang, N.; Jurisson, S. S.; Quinn, T. P. In
vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte
stimulating hormone analogs for specific melanoma targeting. Nucl.
Med. Biol. 1999, 26 (6), 687−693.
(24) Wu, Z.; Li, Z. B.; Cai, W.; He, L.; Chin, F. T.; Li, F.; Chen, X.
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis
and microPET imaging of αvβ3 integrin expression. Eur. J. Nucl. Med.
Mol. Imaging 2007, 34 (11), 1823−1831.
(25) Li, W.; Lang, L.; Niu, G.; Guo, N.; Ma, Y.; Kiesewetter, D. O.;
Shen, B.; Chen, X. N-succinimidyl 4-[18F]-fluoromethylbenzoate-
labeled dimeric RGD peptide for imaging tumor integrin expression.
Amino Acids 2012, 43 (3), 1349−1357.
́
-
Author Contributions
§These authors contributed equally to this work. The
manuscript was written through contributions of all authors.
All authors have given approval to the final version of the
manuscript.
Funding
This work was supported by CLARA (Cancer
Auvergne Rhone-Alpes), the French Directorate-General for
Research and Innovation, the Auvergne Regional Council, the
Puy-de-Dome General Council, Clermont Community, the
́ ̂
opole Lyon
̂
̂
European Union, the European Regional Development Fund,
the French Ligue contre le cancer, and the Bullukian
Foundation.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
The authors thank Cyclopharma Laboratories for helpful
technical supports and for radionuclide providing. The
technical assistance of S. Tarrit is also gratefully acknowledged.
ABBREVIATIONS
■
HPLC, high pressure liquid chromatography; RT, room
temperature; MALDI-TOF, matrix-assisted laser desorbtion/
ionization time-of-flight; iodogen, 1,3,4,6-tetrachloro-3α,6α-
diphenylglucoluril; Xantphos, 4,5-bis(diphenylphosphino)-9,9-
dimethylxanthene; K222, 4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane
REFERENCES
■
(1) Adam, M. J.; Scott, D. J. Radiohalogens for imaging and therapy.
Chem. Soc. Rev. 2005, 34 (2), 153−163.
(2) Wilbur, D. S. Radiohalogenation of proteins: an overview of
radionuclides, labeling methods, and reagents for conjugate labeling.
Bioconjugate Chem. 1992, 3 (6), 433−470.
(3) Dong, S.; Moroder, L.; Budisa, N. Protein iodination by click
chemistry. ChemBioChem 2009, 10 (7), 1149−1151.
(4) Avory, M. Iodine Radiolabelling Method. WO 2011070136, 2011.
(5) Bolton, A. E.; Hunter, W. M. The labeling of proteins to high
specific radioactivities by conjugation to a 125I-containing acylating
agent. Biochem. J. 1973, 133 (3), 529−539.
(6) Vaidyanathan, G.; Zalusky, M. R. Preparation of N-succinimidyl
3-[*I]iodobenzoate: an agent for the indirect radioiodination of
proteins. Nat. Protoc. 2006, 1 (2), 707−713.
(7) Glaser, M.; Luthra, S. K.; Brady, F. Applications of positron-
emitting halogens in PET oncology (Review). Int. J. Oncol. 2003, 22
(2), 253−267.
(8) Zimmermann, R. G. Why are investors not interested in my
radiotracer? The industrial and regulatory constraints in the develop-
ment of radiopharmaceuticals. Nucl. Med. Biol. 2013, 40 (2), 155−166.
́
(9) Chezal, J. M.; Dolle, F.; Madelmont, J. C.; Maisonial, A.; Miot-
Noirault, E.; Moins, N.; Papon, J.; Kuhnast, B.; Tavitian, B. Labelled
Analogues of Halobenzamides as Multimodal Radiopharmaceuticals
and Their Precursors. WO 2009095872, 2009.
(10) Billaud, E. M. F.; Rbah-Vidal, L.; Vidal, A.; Besse, S.; Tarrit, S.;
Askienazy, S.; Maisonial, A.; Moins, N.; Madelmont, J. C.; Miot-
Noirault, E.; Chezal, J. M.; Auzeloux, P. Synthesis, radiofluorination,
and in vivo evaluation of novel fluorinated and iodinated radiotracers
for PET imaging and targeted radionuclide therapy of melanoma. J.
Med. Chem. 2013, 56 (21), 8455−8467.
(11) Wilbur, D. S.; Hamlin, D. K.; Srivastava, R. R.; Burns, H. D.
Synthesis and radioiodination of N-Boc-p-(tri-n-butylstannyl)-L-
172
dx.doi.org/10.1021/ml500423v | ACS Med. Chem. Lett. 2015, 6, 168−172